PMC9663455_01
Chest CT scans of the patient. (A) Scans performed before alectinib therapy. (B) On the 30th day of alectinib therapy, chest CT showed tumor shrinkage. (C) On the 102nd day after alectinib therapy, chest CT showed scattered GGOs involving both lungs and tumor shrinkage. (D) On the 185th day of alectinib therapy, chest CT showed diffuse GGOs involving both lungs. (E) GGOs gradually improved after discontinuation of alectinib. (F) At the latest follow-up (2 months later), chest CT showed no recurrence of interstitial lung disease.
fphar-13-944685-g001.jpg
PMC9663455_01_fphar-13-944685-g001.jpg
F1
Chest computed tomography (CT) revealed a lung mass in the left lower lobe (Figure 1A). One month after alectinib administration, chest CT showed tumor shrinkage (Figure 1B) and the swelling of both lower extremities and pain in both knees and ankles were significantly reduced. However, 102 days after initiation of alectinib therapy, chest CT revealed new scattered ground glass opacities (GGOs) involving both lungs (Figure 1C). On the 185th day of alectinib treatment, she was admitted to our department with progressive dyspnea and chest CT showed diffuse GGOs in both lungs (Figure 1D). Chest CT revealed near-complete resolution of GGOs (Figure 1E). At the recent follow-up (2 months later), she had no symptoms of dyspnea with no recurrence of ILD in chest CT (Figure 1F).